Spinocerebellar Ataxia Type 3 (SCA3, also known as Machado-Joseph Disease) belongs to the family of polyglutamine-dependent neurodegenerative disorders that also includes Huntington's Disease and several other SCAs. SCA3, which is the most common dominant ataxia in the world, is caused by large expansions in the polyglutamine tract of the protein ataxin-3. Current therapeutic approaches for the treatment of SCA3 are symptomatic and do not address the core etiology. Animal models of polyglutamine diseases have shown that reducing the levels of the causative protein leads to significant improvement in neuronal pathology and symptoms. This suggests that enhancing the degradation of the ataxin-3 protein provides a reasonable approach to treat SCA3. The long-term goal of my laboratory is to elucidate molecular mechanisms involved in neurodegeneration and neuroprotection. Starting during my postdoctoral work, I focused on pathways involved in protein degradation, and specifically on ataxin-3. In the course of trying to understand the cell biology of ataxin-3 as a point of entry for SCA3 therapy, we made the unexpected finding that the degradation of ataxin-3 is not regulated by ubiquitination in the common sense. Instead, pathogenic ataxin-3 is stabilized by its interaction with the proteasomal shuttle proteins Rad23 and VCP. Our novel finding provided a lead to destabilize pathogenic ataxin-3 for therapy. This strategy is made even more plausible by the ability of cells and organisms to tolerate very low levels of ataxin-3 - in other words, without a restrictive therapeutic window in terms of the cellular levels of ataxin-3. Here, we propose to expand on these exciting findings by determining how ataxin-3 is degraded, with special emphasis on Rad23 and VCP, and by subsequently testing the idea that disrupting these interactions suppresses ataxin-3-dependent degeneration in the genetically tractable model organism Drosophila melanogaster. We then plan to take advantage of this model system to discover novel genes that suppress ataxin-3-dependent degeneration.

Public Health Relevance

Age-dependent neurodegeneration is a major health issue that will worsen as people live longer lives. Mechanisms of neurodegeneration and protective pathways to combat disease are poorly understood. We propose to elucidate the function of specific proteins and cellular pathways that can be used to provide protection from neurodegenerative processes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS086778-04
Application #
9234079
Study Section
Cellular and Molecular Biology of Neurodegeneration Study Section (CMND)
Program Officer
Miller, Daniel L
Project Start
2014-04-01
Project End
2019-03-31
Budget Start
2017-04-01
Budget End
2018-03-31
Support Year
4
Fiscal Year
2017
Total Cost
$299,250
Indirect Cost
$102,375
Name
Wayne State University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Nath, Samir R; Yu, Zhigang; Gipson, Theresa A et al. (2018) Androgen receptor polyglutamine expansion drives age-dependent quality control defects and muscle dysfunction. J Clin Invest 128:3630-3641
Blount, Jessica R; Libohova, Kozeta; Marsh, Gregory B et al. (2018) Expression and Regulation of Deubiquitinase-Resistant, Unanchored Ubiquitin Chains in Drosophila. Sci Rep 8:8513
Murray, Andrew S; Varela, Fausto A; Hyland, Thomas E et al. (2017) Phosphorylation of the type II transmembrane serine protease, TMPRSS13, in hepatocyte growth factor activator inhibitor-1 and -2-mediated cell-surface localization. J Biol Chem 292:14867-14884
Sutton, Joanna R; Blount, Jessica R; Libohova, Kozeta et al. (2017) Interaction of the polyglutamine protein ataxin-3 with Rad23 regulates toxicity in Drosophila models of Spinocerebellar Ataxia Type 3. Hum Mol Genet 26:1419-1431
Das, Banibrata; Rajagopalan, Subramanian; Joshi, Gnanada S et al. (2017) A novel iron (II) preferring dopamine agonist chelator D-607 significantly suppresses ?-syn- and MPTP-induced toxicities in vivo. Neuropharmacology 123:88-99
Tsou, Wei-Ling; Qiblawi, Sultan H; Hosking, Ryan R et al. (2016) Polyglutamine length-dependent toxicity from ?1ACT in Drosophila models of spinocerebellar ataxia type 6. Biol Open 5:1770-1775
Costa, Maria do Carmo; Ashraf, Naila S; Fischer, Svetlana et al. (2016) Unbiased screen identifies aripiprazole as a modulator of abundance of the polyglutamine disease protein, ataxin-3. Brain 139:2891-2908
Yedlapudi, Deepthi; Joshi, Gnanada S; Luo, Dan et al. (2016) Inhibition of alpha-synuclein aggregation by multifunctional dopamine agonists assessed by a novel in vitro assay and an in vivo Drosophila synucleinopathy model. Sci Rep 6:38510
Ristic, Gorica; Tsou, Wei-Ling; Guzi, Ermal et al. (2016) USP5 Is Dispensable for Monoubiquitin Maintenance in Drosophila. J Biol Chem 291:9161-72
Tsou, Wei-Ling; Ouyang, Michelle; Hosking, Ryan R et al. (2015) The deubiquitinase ataxin-3 requires Rad23 and DnaJ-1 for its neuroprotective role in Drosophila melanogaster. Neurobiol Dis 82:12-21

Showing the most recent 10 out of 14 publications